



Published in final edited form as:

Cancer. 2018 October 01; 124(19): 3856–3867. doi:10.1002/cncr.31674.

## Adult Leukemia Survival Trends in the United States by Subtype: A Population-Based Registry Study of 370,994 Patients Diagnosed During 1995-2009

Chris Bailey, MB ChB, MSc, MRCP<sup>1</sup>, Lisa C. Richardson, MD, MPH<sup>2</sup>, Claudia Allemani, MSc, PhD, FHEA, HonMFP<sup>1</sup>, Audrey Bonaventure, MD, PhD<sup>1</sup>, Rhea Harewood, MSc<sup>1</sup>, Angela R. Moore, MPH<sup>2</sup>, Sherri L. Stewart, PhD<sup>2</sup>, Hannah K. Weir, PhD<sup>2</sup>, Michel P. Coleman, MD<sup>1</sup>, and CONCORD Working Group (US members)\*

<sup>1</sup>Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom;

<sup>2</sup>Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

### Abstract

\*CONCORD Working Group (US members): JT George, X Shen (Alabama Statewide Cancer Registry); JT Brockhouse, DK O'Brien (Alaska Cancer Registry); KC Ward (Georgia Comprehensive Cancer Registry; Metropolitan Atlanta Registry); L Almon (Metropolitan Atlanta Registry); J Bates (California State Cancer Registry); R Rycroft (Colorado Central Cancer Registry); L Mueller, C Phillips (Connecticut Tumor Registry); H Brown, B Cromartie (Delaware Cancer Registry); A Schwartz, F Vigneau (Metropolitan Detroit Cancer Surveillance System); JA MacKinnon, B Wohler (Florida Cancer Data System); AR Bayakly (Georgia Comprehensive Cancer Registry); CA Clarke, SL Glaser (Greater Bay Area Cancer Registry); D West (Cancer Registry of Greater California); MD Green, BY Hernandez (Hawaii Tumor Registry); CJ Johnson, D Jozwik (Cancer Data Registry of Idaho); ME Charlton, CF Lynch (State Health Registry of Iowa); B Huang, TC Tucker\* (Kentucky Cancer Registry); D Deapen, L Liu (Los Angeles Cancer Surveillance Program); MC Hsieh, XC Wu (Louisiana Tumor Registry); K Stern (Maryland Cancer Registry); ST Gershman, RC Knowlton (Massachusetts Cancer Registry); J Alverson, GE Copeland (Michigan State Cancer Surveillance Program); DB Rogers (Mississippi Cancer Registry); D Lemons, LL Williamson (Montana Central Tumor Registry); M Hood (Nebraska Cancer Registry); GM Hosain, JR Rees (New Hampshire State Cancer Registry); KS Pawlish, AM Stroup (New Jersey State Cancer Registry); C Key, CL Wiggins (New Mexico Tumor Registry); AR Kahn, MJ Schymura (New York State Cancer Registry); G Leung, C Rao (North Carolina Central Cancer Registry); L Giljahn, B Warther (Ohio Cancer Incidence Surveillance System); A Pate (Oklahoma Central Cancer Registry); M Patil, SS Schubert (Oregon State Cancer Registry); JJ Rubertone, SJ Slack (Pennsylvania Cancer Registry); JP Fulton, DL Rousseau (Rhode Island Cancer Registry); TA Janes, SM Schwartz (Seattle Cancer Surveillance System); SW Bolick, DM Hurley (South Carolina Central Cancer Registry); J Richards, MA Whiteside (Tennessee Cancer Registry); LM Nogueira (Texas Cancer Registry); K Herget, C Sweeney (Utah Cancer Registry); J Martin, S Wang (Virginia Cancer Registry); DG Harrelson, MB Keitheri Cheteri (Washington State Cancer Registry); S Farley, AG Hudson (West Virginia Cancer Registry); R Borchers, L Stephenson (Wisconsin Department of Health Services); JR Espinoza (Wyoming Cancer Surveillance Program); HK Weir (Centers for Disease Control and Prevention); BK Edwards (National Cancer Institute)

**Corresponding author:** Claudia Allemani, MSc, PhD, FHEA, HonMFP, Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; claudia.allemani@lshtm.ac.uk.

#### AUTHOR CONTRIBUTIONS

**Chris Bailey:** Conceptualization, writing—original draft, and formal analysis. **Lisa C. Richardson:** Writing—review and editing and project administration. **Claudia Allemani:** Conceptualization, writing—review and editing, project administration, and funding acquisition. **Audrey Bonaventure:** Data validation and writing—review and editing. **Rhea Harewood:** Data validation, writing, and formal analysis. **Angela R. Moore:** Project administration and writing—review and editing. **Sherri L. Stewart:** Project administration and writing—review and editing. **Hannah K. Weir:** Writing—review and editing, project administration, and funding acquisition. **Michel P. Coleman:** Conceptualization, writing—review and editing, visualization, project administration, and funding acquisition.

Additional supporting information may be found online in the Supporting Information section at the end of the article.

#### CONFLICT OF INTEREST DISCLOSURES

The authors made no disclosures.

**BACKGROUND:** The lifetime risk of developing leukemia in the United States is 1.5%. There are challenges in the estimation of population-based survival using registry data because treatments and prognosis vary greatly by subtype. The objective of the current study was to determine leukemia survival estimates in the United States from 1995 to 2009 according to subtype, sex, geographical area, and race.

**METHODS:** Five-year net survival was estimated using data for 370,994 patients from 43 registries in 37 states and in 6 metropolitan areas, covering approximately 81% of the adult (15–99 years) US population. Leukemia was categorized according to principal subtype (chronic lymphocytic leukemia, acute myeloid leukemia, and acute lymphocytic leukemia), and subcategorized in accordance with the HAEMACARE protocol. We analyzed age-standardized 5-year net survival by calendar period (1995–1999, 2000–2004, and 2005–2009), leukemia subtype, sex, race, and US state.

**RESULTS:** The age-standardized 5-year net survival estimates increased from 45.0% for patients diagnosed during 1995–1999 to 49.0% for those diagnosed during 2000–2004 and 52.0% for those diagnosed during 2005–2009. For patients diagnosed during 2005–2009, 5-year survival was 18.2% (95% confidence interval [95% CI], 17.8%–18.6%) for acute myeloid leukemia, 44.0% (95% CI, 43.2%–44.8%) for acute lymphocytic leukemia, and 77.3% (95% CI, 76.9%–77.7%) for chronic lymphocytic leukemia. For nearly all leukemia subtypes, survival declined in successive age groups above 45 to 54 years. Men were found to have slightly lower survival than women; however, this discrepancy was noted to have fallen in successive calendar periods. Net survival was substantially higher in white than black patients in all calendar periods. There were large differences in survival noted between states and metropolitan areas.

**CONCLUSIONS:** Survival from leukemia in US adults improved during 1995–2009. Some geographical differences in survival may be related to access to care. We found disparities in survival by sex and between black and white patients.

### Keywords

cancer; cancer registries; leukemia; National Program of Cancer Registries; population-based survival; Surveillance, Epidemiology, and End Results (SEER); United States

## INTRODUCTION

The age-standardized incidence rate of all leukemias combined in adults in the United States is 6.9 per 100,000 population per year, with a lifetime risk of developing leukemia of 1.5%.<sup>1</sup> Survival among adults with leukemia has been improving over the last 30 years, with 5-year survival rising from 33% in 1975 to 59% in 2005.<sup>1</sup> As with many cancers, the absolute number of leukemia cases is expected to increase over the coming years, primarily due to the ageing population.<sup>2</sup>

Survival estimates from population-based cancer registries typically are lower than those of clinical trials because eligibility criteria for trial participants often include restrictions based on age or comorbidities.<sup>3</sup> Population-based cancer registries in the United States receive federal support from the National Cancer Institute's Surveillance, Epidemiology, and End Results program<sup>1</sup>; the Centers for Disease Control and Prevention's National Program of

Cancer Registries<sup>4</sup>; or both. These programs collect data including sex, race, tumor behavior, basis of diagnosis, age at diagnosis, and date of death or last known follow-up on all new cancer cases. These data are used to provide information regarding incidence, survival, prevalence, and mortality. This information is crucial to inform policymakers implementing cancer prevention and control strategies.<sup>5</sup>

Leukemias are categorized by the lineage of the cell affected (myeloid vs. lymphoid) and the rapidity of disease progression (acute vs. chronic). Within each category, the malignant cell may originate from different stages of maturation, taking on unique morphological, cytogenetic, and clinical characteristics. As many leukemias are too rare to power robust survival estimates, a consensus grouping of hematological malignancies was formed as part of the European Cancer Registry–based HAEMACARE project on hematologic malignancies.<sup>6</sup> This grouping is based on the World Health Organization classification of Tumours of the Haematopoietic and Lymphoid Tissues.<sup>7</sup>

The CONCORD-2 study established global surveillance of cancer survival in 2015, including data from 279 registries in 67 countries for 25.7 million patients diagnosed during 1995–2009. This included survival estimates for all adult patients with leukemia combined (873,588 patients worldwide), along with 9 other malignancies.<sup>2</sup> As part of a systematic analysis, this project focuses on US adults diagnosed with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL) during the periods 1995–1999, 2000–2004, and 2005–2009 and presents survival by leukemia subtype, sex, race, and US state or metropolitan area.

## MATERIALS AND METHODS

Data for 393,805 adult patients (those aged 15–99 years) diagnosed with leukemia between January 1995 and December 2009 were provided by 43 registries in 37 states and in 6 metropolitan areas that collectively cover approximately 81.0% of the US national population (Fig. 1). The variables in the data set included a unique identifier; sex; age at diagnosis; last known vital status; International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) morphology code; date of diagnosis; race (as self-defined by patients); and basis of diagnosis (morphological/cytological verification, clinical verification, and death certificate only). A total of 10,071 (2.6%) patient records did not meet the eligibility criteria and these patients were excluded. Reasons for exclusion comprised data that were incomplete, patients aged outside the age range of 15 to 99 years, and diagnoses of uncertain or benign behavior. Of records eligible for survival analysis, those with coding and classification errors, invalid dates or date sequences, or incongruence between age and morphology were also excluded. Each registry was issued 3 data quality reports (protocol adherence, exclusions, and editorial) and were invited to correct any inconsistencies identified. In all, 3.3% of patients diagnosed based on death certificate only or whose disease was detected at autopsy were excluded.

We categorized leukemias into 3 principal groups: acute myeloid leukemia (AML; 34.7%), acute lymphocytic leukemia (ALL; 14.0%), and chronic lymphocytic leukemia (CLL;

51.3%). Subtypes of leukemia then were subdivided further into HAEMACARE groups, which were defined by ICD-O-3 morphology codes 9670–9981 (Table 1).

We examined the distribution of age at diagnosis, sex, race, and data quality indicators such as the percentage of diagnoses with microscopic verification and patients lost to follow-up. Patients were grouped into 3 calendar periods of diagnosis: 1995–1999, 2000–2004, and 2005–2009. We used the 5 age groups set out in the International Cancer Survival Standard for age standardization: 15 to 44, 45 to 54, 55 to 64, 65 to 74, and 75 to 99 years.<sup>8</sup> Race was coded as “black,” “white,” and “other.” The basis of diagnosis was coded as “morphologically verified” if there was cytological, histological, or microscopic evidence of verification.

### Statistical Analysis

We estimated 5-year net survival with the estimator of Pohar-Perme et al,<sup>9</sup> implemented with the program *stns*<sup>10</sup> in Stata statistical software (version 14; StataCorp, College Station, Texas).<sup>11</sup> Net survival is the probability of surviving up to a given time since diagnosis after controlling for competing causes of death (background mortality). The cohort approach was used for the calendar periods 1995–1999 and 2000–2004 because at least 5 years of potential follow-up were available for all patients. The period approach was used for patients diagnosed between 2005 and 2009 in which 5 years of follow-up were not available for all patients. This approach provides a robust short-term prediction of the eventual cohort-based survival.<sup>12</sup>

To control for wide differences in background mortality, we used the life tables prepared for the CONCORD-2 study.<sup>13</sup> These contain all-cause mortality rates in the general population of each state or metropolitan area by single year of age, sex, and race, for each calendar year from 1995 to 2009. For patients with cancer whose race was coded as “other,” we used the life tables for all races combined. Robust life tables for black patients were not available in 6 states in which the black population is small (Alaska, Hawaii, Idaho, Montana, New Hampshire, and Wyoming). In those 6 states, survival estimates for black patients are not presented separately.

Age-standardized net survival was estimated for each HAEMACARE group of malignancies, stratified by sex, race, and calendar period. When there were fewer than 10 patients in a given age group, the data were merged with the adjacent age group to create 2 age-specific estimates. When there were two or more age-specific estimates based on fewer than 10 patients, only unstandardized estimates are presented.

Approval for the CONCORD-2 data was obtained from the Ethics and Confidentiality Committee of the UK Health Research Authority (ECC 3–04(i)/2011) and the National Health Service Research Ethics Committee (11/LO/0331). Separate statutory and/or human subjects research approvals were obtained from each cancer registry.

## RESULTS

A total of 370,994 patients were included in the analysis: 89.1% were white, 7.3% were black, and 3.6% were of other race. Men comprised 57.5% of the patients. The median age at the time of diagnosis was 69.3 years.

CLL was the most common leukemia for all age groups with the exception of those aged 15 to 44 years, for whom AML was more frequent (see Supporting Table 1). All leukemias were more common in males. For HAEMACARE groups, the sex disparity was smallest for acute myeloid leukemia (group 22), in which 54.0% of those diagnosed were men (Table 2). Burkitt lymphoma (10.8%) was most common among black patients, and acute (precursor cell) lymphoblastic leukemia was most common among other races (5.4%). The number of cases per state ranged from 649 cases (Alaska) to 47,886 cases (California). The majority of cases (90.9%) were morphologically verified, ranging from 83.4% (Maryland) to 99.3% (Florida) (see Supporting Table 2).

For the US overall, age-standardized 5-year net survival for all sexes, races, and subtypes combined increased from 45.0% (95% confidence interval [95% CI], 44.6%–45.4%) in 1995–1999 to 49.0% (95% CI, 48.7%–49.4%) in 2000–2004, to 52.0% (95% CI, 51.6%–52.3%) in 2005–2009. This represents an absolute increase in 5-year net survival of 4.0% between 1995–1999 and 2000–2004, and 3.0% between 2000–2004 and 2005–2009.

Survival declined in successive age groups from 45 to 54 years for nearly all leukemia subtypes (Table 3). Gains in survival were highest in the younger age groups. For patients with AML between 1995–1999 and 2005–2009, survival increased by 12.1% in those aged 45 to 54 years compared with 1.4% in the those aged 75 to 99 years.

Age-standardized 5-year net survival increased for all 3 principal leukemias (Table 4). The greatest gains were noted among patients with ALL (5.3% between 1995–1999 and 2000–2004 and 3.9% between 2000–2004 and 2005–2009). Among HAEMACARE groups, there were large gains for patients with Burkitt lymphoma (9.5% [95% CI, 5.3%–13.5%] between 1995–1999 and 2000–2004 and 4.9% [95% CI, 1.4%–8.4%] between 2000–2004 and 2005–2009).

For patients diagnosed during 2005–2009, 5-year survival was 18.2% (95% CI, 17.8%–18.6%) for AML, 44.0% (95% CI, 43.2%–44.8%) for ALL, and 77.3% (95% CI, 76.9%–77.7%) for CLL (Table 5). Males were found to have slightly lower survival than females throughout the 15 years between 1995 and 2009. This disparity fell in successive time periods (1.5% in 1995–1999, 1.1% in 2000–2004, and 0.7% in 2005–2009).

Net survival for white patients was substantially higher than that for black patients throughout the 15-year period, with the absolute difference noted to increase (8.3% in 1995–1999, 9.5% in 2000–2004, and 10.9% in 2005–2009) (Fig. 2). Survival was higher for white than for black patients for each of the 11 subtypes of leukemia, except for mature B-cell leukemia, for which the data were sparse (Table 5). The largest racial disparities were noted for Burkitt lymphoma (11.7% in 1995–1999, 14.9% in 2000–2004, and 16.1% in 2005–2009) and CLL/small lymphocytic leukemia (10.7% in 1995–1999, 12.8% in 2000–2004,

and 12.3% in 2005–2009). For patients of “other” races, survival generally was higher than that for white patients; however, the estimates had wider 95% CIs. The range in survival estimates by registry also showed wide geographic disparity: from 40.9% in Mississippi to 56.5% in Seattle, Washington (Table 5). For patients with CLL, AML, and ALL, the racial difference in 5-year net survival was either constant or increasing (Fig. 2).

## DISCUSSION

The current study reports data from 370,994 patients from 43 registries covering approximately 81.0% of the US population over a 15-year time period. Five-year net survival improved from 45.0% during 1995–1999 (95% CI, 44.6%–45.4%) to 49.0% during 2000–2004 (95% CI, 48.7%–49.4%) and 52.0% during 2005–2009 (95% CI, 51.6%–52.3%).

For patients diagnosed between 2005 and 2009, survival estimates were 44.0% for ALL, 18.2% for AML, and 77.3% for CLL. All 3 subtypes of leukemia showed improvements in survival, with gains in 5-year net survival of 9.2% for ALL, of 6.4% for CLL, and of 5.5% for AML from 1995–2009. The survival gains in ALL may be related to the use of the more intensive pediatric protocols in young adults,<sup>14</sup> and the use of tyrosine kinase inhibitors for patients with *BCR-ABL*-positive ALL.<sup>15</sup> Fludarabine-containing regimens were introduced as first-line treatment for patients with CLL in the 1990s, when these regimens were shown to have higher event-free survival than chlorambucil.<sup>16</sup> The introduction of rituximab likely also has improved survival.<sup>17</sup> Other than acute promyelocytic leukemia, anthracycline-based and cytarabine-based chemotherapy has been the mainstay of treatment for AML for many years. The more gradual survival gains observed in patients with AML are likely due to improvements in supportive care and stem cell transplantation.<sup>18</sup> In addition to treatment, better residual disease monitoring and refining of diagnostic techniques such as flow cytometry, polymerase chain reaction, and fluorescence in situ hybridization, resulting in better prognostic precision and more effective management strategies, have contributed to survival gains in patients with leukemia.<sup>19</sup>

For patients with AML, the modest survival gains over 15 years can be partially explained by minimal improvements (1.4%) among the elderly patients (75–99 years), for whom the disease burden is higher when compared with patients with ALL. Elderly patients often are less tolerant of cytotoxic treatment modalities due to frailty and comorbidities.<sup>20</sup> Moreover, the disease itself has a different cytogenetic and molecular profile in elderly patients, which may be explained by prior chemotherapy or radiotherapy for previous malignancies or hematological disorders such as myelodysplastic syndrome.<sup>21</sup>

Survival was consistently found to be higher for white than for black patients for nearly all subtypes of leukemia in all registries and throughout the 15 years between 1995 and 2009. For patients with ALL and AML, the racial difference in 5-year net survival is increasing. The gap in 5-year survival from acute leukemia between non-Hispanic white and African American or Hispanic patients was shown to increase between 1992 and 1996 and between 2002 and 2006.<sup>22</sup> This racial disparity is well established, and socioeconomic, cultural, and biological differences all have been put forward as contributors.<sup>23</sup> In the case of AML, it



was noted that nonwhite ethnic groups were less likely to undergo matched unrelated hematopoietic stem cell transplantation due to lower donor availability.<sup>24</sup> Among patients with leukemia who were randomized to clinical trials, it was shown that racial disparities in survival disappear after controlling for prognostic factors and socioeconomic status.<sup>25</sup> In the clinical trial setting among patients with ovarian cancer, Abdel-Rahman et al showed that there was no socioeconomic inequality in survival outcomes (ie, when access to treatment is equal, these disparities disappear).<sup>26</sup> Reducing inequities in cancer care may go some way toward reducing this disparity.

Using data from population-based cancer registries minimizes the selection bias associated with variably defined catchment areas in hospital-based registries. Of the 393,805 patient records submitted from registries to the CONCORD study, only 2.6% were ineligible due to incomplete data, coding errors, or being outside the age range, or of benign behavior. Of the remaining records, 3.3% were registered solely from a death certificate or at autopsy, and were excluded because the date of diagnosis was unknown. The proportion of patients lost to follow-up was very low (0.8%). Net survival estimates for “other races” may be subjected to bias; these estimates are based on the background mortality of all races in the population because robust, state-specific life tables for individual racial groups were not available. As an example, Asian/Pacific Islander women in low unemployment areas have a life expectancy of up to 90 years<sup>27</sup> when compared with the population average of 80.7 years in the same areas. Net survival figures among this group of patients would be conservative due to the overestimation of background mortality by using life tables for all races combined. It is interesting to note that 5-year cause-specific survival for adults diagnosed with leukemia was 10.1% lower in Asian/Pacific Islanders than whites in 18 areas covered by the Surveillance Epidemiology and End Results program during 2008–2014, whereas the difference between the median age-standardized 5-year net survival estimates for leukemia in Asian and western populations in the CONCORD-3 study<sup>28</sup> became smaller during the period 2000–2014. This suggests that a large part of the difference in leukemia survival between whites and Asian/Pacific Islanders in the SEER program is likely to be attributable to better access to treatment, rather than race.

Innovations in leukemia treatment over the last 50 years are reflected in the survival gains presented in the current study, and are promoted through health policy and cancer control programs. The National Comprehensive Cancer Control Program (NCCCP), administered by the Centers for Disease Control and Prevention since 1998, funds all states, the District of Columbia, several tribes and tribal organizations, Puerto Rico, and several Pacific Island jurisdictions. Treatment and survival-specific initiatives described in NCCCP cancer plans include the strategic dissemination of information and educational resources among providers, the general public, and patients with hematologic cancer and their families and increased awareness regarding the nature of the disease, disparities that exist among minority and underserved populations, treatment options, availability of clinical trials, and support services for survivors. The continuance of these efforts is in part dependent on sustainable partnerships that can facilitate more effective community-clinical linkages and changes to ensure access to quality patient care among all patients. Future NCCCP efforts in these areas that specifically target black men and women with leukemia may help to alleviate the racial differences in survival.

Further highlighted in the current study is the issue of classification when making population-based survival comparisons in patients with leukemia. Rare leukemias within a group undoubtedly have an impact on survival, especially if they are more prevalent in certain populations. HAEMACARE<sup>6</sup> and INTERLymph<sup>29</sup> are 2 projects that address this issue. The real challenge to producing sub-type-specific estimates in population-based studies is that the data usually are sparse and estimates are imprecise.

## CONCLUSIONS

Survival from leukemia in the United States has improved between 1995 and 2009, increasing in each successive 5-year period. The results of the current study have identified major differences between disease subtype, sex, and race, with the relative gains in survival mirroring the treatment milestones that have been achieved for each subtype. Although the survival gap between sexes appears to be converging, the racial gap has not. This could have many causes, but addressing the sociopolitical, economic, and cultural constraints that create barriers to treatment, trial enrolment, and donor availability will be required to reduce inequities in access to quality cancer care.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## FUNDING SUPPORT


Supported by the US Centers for Disease Control and Prevention (12FED03123 and ACO12036).

## REFERENCES

1. Howlader N, Noone AM, Krapcho M, eds. In: SEER Cancer Statistics Review, 1975–2014. National Cancer Institute: Bethesda, MD; 2017.
2. Allemani C, Weir HK, Carreira H, et al. CONCORD Working Group. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015;385:977–1010. [PubMed: 25467588]
3. Unger JM, Barlow WE, Martin DP, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. *J Natl Cancer Inst*. 2014;106:dju002. [PubMed: 24627276]
4. Wingo PA, Jamison PM, Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). *Cancer Causes Control*. 2003;14:175–193. [PubMed: 12749723]
5. Coleman MP. Cancer survival: global surveillance will stimulate health policy and improve equity. *Lancet*. 2014;383:564–573. [PubMed: 24351320]
6. Maynadie M, De Angelis R, Marcos-Gragera R, et al. HAEMACARE Working Group. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. *Haematologica*. 2013;98:230–238. [PubMed: 22983589]
7. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues WHO/IARC Classification of Tumours. No. 2. 4th ed Geneva: World Health Organization; 2008.
8. Corazzari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. *Eur J Cancer*. 2004;40:2307–2316. [PubMed: 15454257]
9. Pohar-Perme M, Stare J, Estève J. On estimation in relative survival. *Biometrics*. 2012;68:113–120. [PubMed: 21689081]




10. Clerc-Urmès I, Grzebyk M, Hédelin G. Net survival estimation with stns. *Stata J.* 2014;14:87–102.
11. StataCorp LLC. STATA Statistical Software, Version 14 [computer program]. College Station, TX: StataCorp LLC; 2015.
12. Brenner H, Gefeller O, Hakulinen T. Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. *Eur J Cancer.* 2004;40:326–335. [PubMed: 14746849]
13. Baili P, Micheli A, DeAngelis R, et al. CONCORD Working Group. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). *Tumori.* 2008;94:658–668. [PubMed: 19112937]
14. Adolescents Stock W. and young adults with acute lymphoblastic leukemia. *Hematology Am Soc Hematol Educ Program.* 2010;2010:21–29. [PubMed: 21239766]
15. Yanada M, Takeuchi J, Sugiura I, et al. Japan Adult Leukemia Study Group. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL–positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. *J Clin Oncol.* 2006;24:460–466. [PubMed: 16344315]
16. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. *N Engl J Med.* 2000;343:1750–1757. [PubMed: 11114313]
17. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. *Blood.* 1997;90:2188–2195. [PubMed: 9310469]
18. Dinmohamed AG, Visser O, van Norden Y, et al. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012. *Leukemia.* 2016;30:24–31. [PubMed: 26183645]
19. Leukaemia Greaves M. ‘firsts’ in cancer research and treatment. *Nat Rev Cancer.* 2016;16:163–172. [PubMed: 26911190]
20. Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma—a Swedish population-based study. *BMC Cancer.* 2015;15:850. [PubMed: 26537111]
21. Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. *Leuk Res Rep.* 2016;6:1–7. [PubMed: 27408788]
22. Pulte D, Redaniel MT, Brenner H, Jeffreys M. Changes in survival by ethnicity of patients with cancer between 1992–1996 and 2002–2006: is the discrepancy decreasing? *Ann Oncol.* 2012;23:2428–2434. [PubMed: 22396445]
23. Brawley OW. Is race really a negative prognostic factor for cancer? *J Natl Cancer Inst.* 2009;101:970–971. [PubMed: 19567421]
24. Pidala J, Kim J, Schell M, et al. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. *Bone Marrow Transplant.* 2013;48:346–350. [PubMed: 22863723]
25. Albain KS, Unger JM, Crowley JJ, Coltman CA, Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. *J Natl Cancer Inst.* 2009;101:984–992. [PubMed: 19584328]
26. Abdel-Rahman ME, Butler J, Sydes MR, et al. ICON2 and ICON3 investigators. No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. *Br J Cancer.* 2014;111:589–597. [PubMed: 24918817]
27. Singh GK, Siahpush M. Inequalities in US life expectancy by area unemployment level, 1990–2010. *Scientifica (Cairo).* 2016;2016:8290435. [PubMed: 27073716]
28. Allemani C, Matsuda T, DiCarlo V, et al. CONCORD Working Group. Global surveillance of trends in cancer survival 2000–14 (CONCORD- 3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet.* 2018;391:1023–1075. [PubMed: 29395269]
29. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. *Blood.* 2010;116:e90–e98. [PubMed: 20699439]



**Figure 1.**

Participating registries in the analysis of leukemia survival trends in the United States, 1995–2009. †Surveillance, Epidemiology, and End Results registries; \*National Program of Cancer Registries (bold); Metropolitan registries (italics).



**Figure 2.**

The absolute age-standardized 5-year net survival difference (shown as percentage) in principal groups between black (B), white (W), and other (O) races for leukemias in the United States, 1995–2009. The boxes represent the absolute difference between B and W races. Point estimates for B, W, and O races are shown on the x-axis. The 95% confidence intervals for W and B patients are shown by error bars. ALL indicates acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia.

**TABLE 1.**  
HAEMACARE grouping of leukemias with corresponding ICD-O-3 morphology codes

HAEMACARE Group	Description	ICD-O-3 Morphology Codes
<b>Acute lymphocytic leukemia</b>		
11	Burkitt	9687-Burkitt lymphoma, NOS
		9826-Burkitt cell leukemia
15	Lymphoblastic lymphoma/acute (precursor cell) lympho-blastic leukemia	9727-Precursor cell lymphoblastic lymphoma, NOS
		9728-Precursor B-cell lymphoblastic lymphoma
		9729-Precursor T-cell lymphoblastic lymphoma
		9835-Precursor cell lymphoblastic leukemia, NOS
		9836-Precursor B-cell lymphoblastic leukemia
		9837-Precursor T-cell lymphoblastic leukemia
20	Leukemia, NOS	9800-Leukemia, NOS
		9801-Acute leukemia, NOS
<b>Acute myeloid leukemia</b>	Myeloid leukemia, NOS	9805-Acute biphenotypic leukemia
		9860-Myeloid leukemia, NOS
		9840-Acute myeloid leukemia, M6 type
		9861-Acute myeloid leukemia, NOS
		9866-Acute promyelocytic leukemia (APML)
		9867-Acute myelomonocytic leukemia
		9870-Acute basophilic leukemia
		9871-Acute myeloid leukemia with abnormal marrow eosinophils
		9872-Acute myeloid leukemia minimal differentiation
		9873-Acute myeloid leukemia, without maturation
22	Acute myeloid leukemia	9874-Acute myeloid leukemia with maturation
		9891-Acute monocytic leukemia
		9895-Acute myeloid leukemia, with multilineage dysplasia
		9896-Acute myeloid leukemia, t(8,21) (q22,q22)
		9897-Acute myeloid leukemia, 11q23 abnormalities
		9910-Acute megakaryoblastic leukemia

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

HAEMACARE Group	Description	ICD-O-3 Morphology Codes
Chronic lymphocytic leukemia		
6	Chronic lymphocytic leukemia/small lymphocytic lymphoma	9670-Malignant lymphoma, small B lymphocytic, NOS 9823-B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
17	Mature B-cell leukemia	9833-Prolymphocytic leukemia, B-cell type
18	Mature B-cell leukemia, hairy cell	9940-Hairy cell leukemia
19	Lymphatic leukemia	9820-Lymphoid leukemia, NOS 9832-Prolymphocytic leukemia, NOS

Abbreviations: ICD-O-3, International Classification of Diseases for Oncology, 3rd Edition; NOS, not otherwise specified.

TABLE 2.

Distribution (%) of leukemias in the United States, by sex and by race: 1995–2009

HAEMACARE Group	Sex						Race							
	Male			Female			White			Black			Other	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Acute lymphocytic leukemia	51,958	30,519	58.7	21,439	41.3	44,974	86.6	4,556	8.8	2,428	4.7			
11 Burkitt	9,665	6,764	70.0	2,901	30.0	8,171	84.5	1,041	10.8	453	4.7			
15 Lymphoblastic lymphoma/acute (precursor cell) lymphoblastic leukemia	25,421	14,956	58.8	10,465	41.2	21,859	86.0	2,187	8.6	1,375	5.4			
20 Leukemia, NOS	16,872	8,799	52.2	8,073	47.8	14,944	88.6	1,328	7.9	600	3.6			
Acute myeloid leukemia	128,626	69,488	54.0	59,138	46.0	113,280	88.1	10,136	7.9	5,210	4.1			
21 Myeloid leukemia, NOS	4,457	2,439	54.7	2,018	45.3	3,921	88.0	392	8.8	144	3.2			
22 Acute myeloid leukemia	124,169	67,049	54.0	57,120	46.0	109,359	88.1	9,744	7.8	5,066	4.1			
Chronic lymphocytic leukemia	190,410	113,296	59.5	77,114	40.5	172,272	90.5	12,436	6.5	5,702	3.0			
6 Chronic lymphocytic leukemia/small lymphocytic lymphoma	176,918	103,587	58.6	73,331	41.4	159,873	90.4	11,831	6.7	5,214	2.9			
17 Mature B-cell leukemia	474	301	63.5	173	36.5	431	90.9	29	6.1	14	3.0			
18 Mature B-cell leukemia, hairy cell	9,556	7,375	77.2	2,181	22.8	8,887	93.0	305	3.2	364	3.8			
19 Lymphatic leukemia	3,462	2,033	58.7	1,429	41.3	3,081	89.0	271	7.8	110	3.2			
Total	370,994	213,303	57.5	157,691	42.5	330,526	89.1	27,128	7.3	13,340	3.6			

Abbreviations: NOS, not otherwise specified.



**TABLE 3.**  
Age-specific net survival estimates by leukemia subtype (HAEMACARE group), United States: 1995–2009

HAEMACARE group		Age Group (Years)														
		15–44		45–54		55–64		65–74		75–99						
		NS	95%CI	NS	95%CI	NS	95%CI	NS	95%CI	NS	95%CI	NS	95%CI			
Acute lymphocytic leukemia																
Burkitt																
11	1995–1999	46.1	42.8	49.4	34.5	29.0	39.9	38.0	31.3	44.7	29.3	23.3	35.3	15.1	9.4	20.9
	2000–2004	58.3	55.7	61.0	36.9	33.1	40.7	42.3	37.6	46.9	34.6	30.0	39.1	24.6	19.5	29.7
	2005–2009	63.6	61.2	66.0	47.9	44.1	51.7	47.4	43.1	51.7	40.9	36.0	45.9	19.5	15.3	23.7
Lymphoblastic lymphoma/acute (precursor cell) lymphoblastic leukemia																
15	1995–1999	46.0	44.3	47.7	25.5	22.4	28.7	18.4	15.6	21.3	12.3	10.0	14.7	8.0	5.7	10.2
	2000–2004	49.7	48.2	51.2	30.0	27.2	32.7	21.7	19.1	24.2	15.1	12.7	17.6	8.9	6.7	11.2
	2005–2009	52.7	51.3	54.2	32.1	29.5	34.7	25.6	23.0	28.2	18.0	15.4	20.6	10.7	8.3	13.1
Leukemia, NOS																
20	1995–1999	40.8	35.8	45.7	28.1	23.1	33.0	22.4	18.9	25.9	13.6	11.7	15.4	8.0	6.7	9.2
	2000–2004	44.5	39.9	49.1	36.8	31.4	42.3	28.8	24.9	32.7	19.5	17.0	22.0	9.3	7.9	10.6
	2005–2009	52.8	47.9	57.8	44.2	38.3	50.1	33.5	29.3	37.8	26.7	23.4	30.0	10.9	9.3	12.5
Acute myeloid leukemia																
Myeloid leukemia, NOS																
21	1995–1999	39.6	31.4	47.8	41.4	30.7	52.2	24.0	17.3	30.8	15.0	10.7	19.4	6.0	3.1	9.0
	2000–2004	56.0	48.2	63.8	43.1	34.3	52.0	34.3	27.6	40.9	20.6	16.1	25.2	12.6	9.3	15.8
	2005–2009	64.7	57.6	71.8	50.3	41.6	58.9	43.7	36.4	51.1	26.3	21.0	31.6	13.5	10.1	16.9
Acute myeloid leukemia																
22	1995–1999	41.4	40.1	42.8	25.7	24.2	27.2	15.4	14.3	16.4	7.0	6.4	7.5	3.1	2.6	3.5
	2000–2004	45.9	44.7	47.1	32.8	31.4	34.1	18.9	18.0	19.9	9.3	8.6	9.9	3.6	3.3	4.0
	2005–2009	49.0	47.8	50.2	37.8	36.5	39.2	22.6	21.6	23.6	11.4	10.7	12.1	4.5	4.0	4.9
Chronic lymphocytic leukemia																
Chronic lymphocytic leukemia/small lymphocytic lymphoma																
6	1995–1999	81.4	79.4	83.4	82.1	80.9	83.3	78.2	77.2	79.2	71.1	70.2	72.0	57.0	55.7	58.3
	2000–2004	86.2	84.5	88.0	86.2	85.2	87.2	83.2	82.5	84.0	76.2	75.4	77.0	61.1	60.0	62.1

HAEMACARE group	Age Group (Years)											
	15-44			45-54			55-64			65-74		
	NS	95%CI	NS	95%CI	NS	95%CI	NS	95%CI	NS	95%CI	NS	95%CI
2005-2009	<b>87.6</b>	85.9	89.3	<b>87.9</b>	87.1	88.8	<b>84.4</b>	83.6	85.1	<b>78.1</b>	77.3	78.9
Mature B-cell leukemia												
17	1995-1999	-	-	-	-	-	-	-	-	-	-	-
	2000-2004	-	-	<b>45.7</b>	15.0	76.3	<b>46.4</b>	28.6	64.1	<b>45.0</b>	30.1	59.8
	2005-2009	<b>84.2</b>	56.7	100.0	<b>54.9</b>	32.3	77.4	<b>46.9</b>	30.6	63.1	<b>56.2</b>	41.8
Mature B-cell leukemia, hairy cell												
18	1995-1999	<b>96.9</b>	95.1	98.8	<b>96.7</b>	94.9	98.6	<b>91.0</b>	87.8	94.3	<b>87.2</b>	83.0
	2000-2004	<b>98.0</b>	96.5	99.5	<b>97.4</b>	95.9	98.9	<b>97.1</b>	94.9	99.3	<b>94.0</b>	90.4
	2005-2009	<b>99.6</b>	98.6	100.0	<b>97.8</b>	96.3	99.3	<b>97.1</b>	95.0	99.2	<b>95.6</b>	92.1
Lymphatic leukemia												
19	1995-1999	<b>61.1</b>	50.2	72.1	<b>53.7</b>	45.0	62.5	<b>53.8</b>	46.6	60.9	<b>44.8</b>	39.0
	2000-2004	<b>63.6</b>	52.5	74.7	<b>64.8</b>	55.2	74.4	<b>57.7</b>	49.7	65.8	<b>55.4</b>	48.5
	2005-2009	<b>69.5</b>	57.6	81.5	<b>69.1</b>	58.0	80.1	<b>65.9</b>	57.8	73.9	<b>64.9</b>	57.6
<b>All leukemias</b>												
	1995-1999	<b>50.3</b>	49.4	51.2	<b>55.5</b>	54.5	56.5	<b>53.4</b>	52.6	54.3	<b>44.8</b>	44.1
	2000-2004	<b>54.5</b>	53.7	55.3	<b>59.4</b>	58.6	60.2	<b>57.6</b>	56.9	58.3	<b>49.3</b>	48.7
	2005-2009	<b>57.6</b>	56.8	58.4	<b>62.8</b>	62.0	63.6	<b>60.6</b>	59.9	61.3	<b>53.0</b>	52.3

Abbreviations: 95% CI, 95% confidence interval; NOS, not otherwise specified; NS, net survival.

**TABLE 4.**  
Age-standardized 5-year net survival estimates for leukemias by calendar period, sex, and race

HAEMACARE group	Sex						Race					
	All			Male			Female			White		
	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI
<b>Acutelymphocytic leukemia</b>												
11 Burkitt												
1995–1999	34.8	33.8	35.7	33.4	32.3	34.6	37.2	35.6	38.8	35.4	34.4	36.5
2000–2004	40.1	39.2	40.9	40.0	38.9	41.0	40.3	38.9	41.7	40.9	40.0	41.9
2005–2009	44.0	43.2	44.8	44.0	43.0	45.0	44.3	42.9	45.7	44.7	43.8	45.6
1995–1999	39.4	37.1	41.7	37.8	35.2	40.6	45.1	40.6	50.1	40.6	38.1	43.1
2000–2004	48.8	47.1	50.7	48.0	45.9	50.2	51.9	48.5	55.6	50.2	48.3	52.3
2005–2009	53.7	52.1	55.4	52.9	51.0	54.9	56.2	53.0	59.6	55.9	54.1	57.8
15 Lymphoblastic lymphoma/acute (precursor cell) lymphoblastic leukemia												
1995–1999	34.0	32.9	35.2	33.1	31.7	34.5	35.6	33.8	37.5	34.7	33.5	35.9
2000–2004	37.4	36.4	38.4	37.5	36.2	38.8	37.2	35.6	39.0	38.0	36.9	39.1
2005–2009	40.3	39.3	41.3	40.6	39.3	41.9	40.1	38.5	41.8	40.8	39.7	41.9
20 Leukemia, NOS												
1995–1999	31.7	28.8	34.9	28.3	24.4	32.7	35.4	31.3	40.2	32.5	29.2	36.2
2000–2004	36.2	33.4	39.1	34.2	30.6	38.2	38.7	34.7	43.3	37.9	34.8	41.3
2005–2009	43.2	40.3	46.4	38.8	34.9	43.2	48.6	44.3	53.3	42.7	39.4	46.3
<b>Acute myeloid leukemia</b>												
21 Myeloid leukemia, NOS												
1995–1999	12.7	12.3	13.0	11.7	11.2	12.2	13.9	13.3	14.5	12.8	12.4	13.2
2000–2004	15.6	15.3	16.0	14.7	14.3	15.2	16.7	16.2	17.3	15.7	15.4	16.1
2005–2009	18.2	17.8	18.6	17.3	16.8	17.8	19.3	18.8	19.9	18.4	18.0	18.8
1995–1999	19.4	16.9	22.2	19.6	16.4	23.4	19.0	15.5	23.2	21.0	18.3	24.1
2000–2004	26.6	24.2	29.3	26.2	23.1	29.8	26.6	23.0	30.7	25.9	23.3	28.7
2005–2009	32.2	29.5	35.0	30.9	27.6	34.6	33.8	29.8	38.4	31.5	28.7	34.6
22 Acute myeloid leukemia												
1995–1999	12.4	12.1	12.8	11.4	11.0	11.9	13.7	13.1	14.3	12.5	12.1	12.9

HAEMACARE group	Sex						Race					
	All			Male			Female			White		
	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI
2000–2004	15.2	14.9	15.6	14.3	13.9	14.8	16.4	15.9	16.9	15.4	15.0	15.8
2005–2009	17.8	17.4	18.1	16.9	16.4	17.4	18.9	18.3	19.5	17.9	17.5	18.3
<b>Chronic lymphocytic leukemia</b>												
1995–1999	70.9	70.4	71.5	68.7	68.0	69.5	74.0	73.3	74.8	71.6	71.0	72.1
2000–2004	75.6	75.2	76.1	73.3	72.7	73.9	79.1	78.5	79.8	76.3	75.8	76.8
2005–2009	77.3	76.9	77.7	74.9	74.3	75.5	80.8	80.2	81.4	77.7	77.3	78.2
6 Chronic lymphocytic leukemia/small lymphocytic lymphoma												
1995–1999	70.7	70.1	71.2	68.1	67.3	68.9	74.3	73.5	75.1	71.3	70.8	71.9
2000–2004	75.3	74.9	75.8	72.6	72.0	73.2	79.2	78.6	79.9	76.0	75.5	76.5
2005–2009	76.9	76.5	77.3	74.2	73.6	74.8	80.8	80.1	81.4	77.4	76.9	77.8
17 Mature B-cell leukemia												
1995–1999	-	-	-	-	-	-	-	-	-	-	-	-
2000–2004	37.8	30.7	46.5	36.4 <sup>a</sup>	26.1 <sup>a</sup>	46.7 <sup>a</sup>	42.8 <sup>a</sup>	28.6 <sup>a</sup>	57.1 <sup>a</sup>	36.3 <sup>a</sup>	27.7 <sup>a</sup>	45.0 <sup>a</sup>
2005–2009	49.2	42.3	57.2	47.0	39.4	56.2	45.6	35.3	58.9	46.5	39.3	55.2
18 Mature B-cell leukemia, hairy cell												
1995–1999	85.1	82.4	87.9	86.1	82.7	89.6	81.6	76.9	86.5	85.1	82.4	88.0
2000–2004	89.0	86.8	91.2	89.1	86.4	91.9	87.5	83.6	91.5	89.1	86.9	91.5
2005–2009	88.9	86.8	91.1	88.9	86.3	91.6	88.5	84.8	92.3	88.6	86.4	90.8
19 Lymphatic leukemia												
1995–1999	40.3	39.3	41.3	40.6	39.3	41.9	40.1	38.5	41.8	40.8	39.7	41.9
2000–2004	45.1	42.0	48.4	42.2	38.5	46.4	48.9	44.0	54.5	45.6	42.4	49.1
2005–2009	52.8	49.4	56.5	48.0	43.5	53.0	60.0	55.0	65.3	52.8	49.2	56.7
<b>All leukemias</b>												
1995–1999	45.0	44.6	45.4	44.3	43.8	44.8	45.8	45.2	46.3	45.6	45.3	46.0
2000–2004	49.0	48.7	49.4	48.5	48.1	48.9	49.6	49.1	50.1	49.7	49.3	50.0
2005–2009	52.0	51.6	52.3	51.6	51.2	52.1	52.3	51.8	52.8	52.5	52.1	52.8

Abbreviations: 95% CI, 95% confidence interval; NOS, not otherwise specified; NS, net survival.

Unstandardized estimates.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**TABLE 5.**  
Age-standardized 5-year net survival estimates by registry, stratified by race: 1995–2009

Registry	All Races			White			Black			Other		
	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI
Alabama	45.9	44.2	47.6	47.0	45.2	48.9	37.1	33.3	41.3	91.7	78.7	100.0
Alaska	50.8	46.0	56.0	54.2	49.2	59.7	-	-	-	21.9	13.5	35.6
California	45.3	44.7	45.9	45.9	45.3	46.5	38.7	36.2	41.4	44.5	42.5	46.7
Greater Bay Area <sup>a</sup>	48.4	47.1	49.8	50.4	48.9	51.9	41.8	36.7	47.7	38.9	35.4	42.7
Greater California <sup>a</sup>	44.1	43.3	44.9	44.2	43.4	45.0	38.9	34.4	43.9	47.2	43.7	51.1
Los Angeles <sup>a</sup>	45.5	44.4	46.7	46.4	45.2	47.7	36.9	33.4	40.7	46.6	43.0	50.4
Colorado	50.8	49.3	52.5	50.1	48.5	51.8	38.2	29.0	50.5	83.6	75.3	92.8
Connecticut	50.9	49.3	52.5	51.4	49.7	53.0	40.6	33.8	48.7	72.2	59.8	87.1
Delaware	44.5	41.2	48.2	45.2	41.7	49.1	36.5	28.5	46.8	66.8 <sup>b</sup>	42.5 <sup>b</sup>	91.1 <sup>b</sup>
Florida	50.5	49.8	51.2	51.2	50.5	51.9	40.6	38.0	43.5	55.1	49.2	61.7
Georgia	47.9	46.4	49.5	49.2	47.5	50.9	43.4	40.0	47.1	45.7	35.3	59.0
Atlanta <sup>a</sup>	48.0	45.7	50.4	50.5	47.9	53.2	41.1	36.5	46.3	27.9	19.6	39.7
Hawaii	43.8	40.8	47.0	57.6	52.5	63.1	-	-	-	34.9	31.5	38.8
Idaho	50.8	48.2	53.6	51.2	48.6	53.9	-	-	-	29.2 <sup>b</sup>	10.1 <sup>b</sup>	48.2 <sup>b</sup>
Iowa	52.9	51.3	54.5	52.8	51.3	54.4	35.0 <sup>b</sup>	17.9 <sup>b</sup>	52.1 <sup>b</sup>	86.3 <sup>b</sup>	72.9 <sup>b</sup>	99.7 <sup>b</sup>
Kentucky	49.3	47.8	50.8	49.5	47.9	51.1	41.4	34.9	49.1	79.3 <sup>b</sup>	67.1 <sup>b</sup>	91.7 <sup>b</sup>
Louisiana	45.1	43.6	46.6	47.1	45.4	48.8	37.3	34.0	40.9	56.7 <sup>b</sup>	40.3 <sup>b</sup>	73.2 <sup>b</sup>
Maryland	41.3	39.7	43.0	42.0	40.3	43.9	36.2	32.4	40.5	63.2	53.8	74.3
Massachusetts	49.9	48.7	51.2	49.6	48.3	50.9	45.4	38.7	53.3	76.8	68.4	86.3
Michigan	47.6	46.7	48.5	47.7	46.8	48.7	39.3	36.3	42.5	75.5	68.3	83.4
Detroit <sup>a</sup>	47.8	46.4	49.3	49.1	47.5	50.8	40.0	36.6	43.8	69.0	58.1	82.0
Mississippi	40.9	37.5	44.6	41.8	38.1	45.9	38.7	31.8	47.1	31.3	34.8	59.2
Montana	49.8	46.7	53.1	49.5	46.4	52.9	-	-	-	58.2	45.7	74.0
Nebraska	51.3	49.2	53.6	50.9	48.8	53.2	36.4 <sup>b</sup>	21.1 <sup>b</sup>	51.7 <sup>b</sup>	81.8 <sup>b</sup>	70.6 <sup>b</sup>	93.0 <sup>b</sup>



Registry	All Races			White			Black			Other		
	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI
New Hampshire	55.4	52.7	58.2	55.2	52.6	58.1	-	-	60.7 <sup>b</sup>	39.5 <sup>b</sup>	81.9 <sup>b</sup>	72.2
New Jersey	49.9	48.9	50.9	50.8	49.7	51.8	36.6	33.1	64.2	57.0	72.2	39.5
New Mexico	52.5	50.1	55.0	53.3	50.9	55.8	40.7 <sup>b</sup>	24.2 <sup>b</sup>	57.3 <sup>b</sup>	19.2	39.5	57.5
New York	48.8	48.1	49.5	49.9	49.1	50.6	38.6	36.3	52.3	47.7	57.5	63.8
North Carolina	48.5	47.3	49.7	49.4	48.1	50.7	43.4	40.0	53.1	44.2	63.8	71.5
Ohio	47.0	45.7	48.2	47.2	45.9	48.5	41.0	36.7	61.6	53.0	71.5	56.0
Oklahoma	42.3	40.6	44.1	42.6	40.8	44.5	28.1	21.6	47.5	40.3	56.0	74.1
Oregon	48.8	47.1	50.6	48.3	46.6	50.1	43.8	31.3	63.6	54.6	74.1	73.0
Pennsylvania	48.1	47.3	48.9	48.2	47.4	49.1	40.2	36.8	66.9	61.3	73.0	79.9 <sup>b</sup>
Rhode Island	48.4	45.4	51.5	48.9	45.9	52.1	17.4	9.0	54.3 <sup>b</sup>	28.8 <sup>b</sup>	79.9 <sup>b</sup>	85.7
South Carolina	46.9	45.3	48.6	48.7	46.8	50.6	37.9	34.3	70.3	57.7	85.7	75.0
Tennessee	47.5	45.2	49.8	48.3	45.9	50.7	35.5	29.6	52.9	37.3	75.0	76.5
Texas	50.4	49.6	51.1	50.5	49.8	51.3	44.0	41.3	70.8	65.5	76.5	60.5 <sup>b</sup>
Utah	50.9	48.5	53.4	51.0	48.6	53.6	41.4 <sup>b</sup>	11.3 <sup>b</sup>	45.8 <sup>b</sup>	31.0 <sup>b</sup>	60.5 <sup>b</sup>	61.4
Washington	55.4	54.2	56.7	55.6	54.3	56.9	49.9	39.5	54.8	48.9	61.4	49.5
Seattle <sup>a</sup>	56.5	55.0	58.1	57.4	55.8	58.9	51.6	40.3	42.2	35.9	49.5	100.0 <sup>b</sup>
West Virginia	46.0	43.9	48.3	45.8	43.7	48.1	49.6 <sup>b</sup>	35.5 <sup>b</sup>	71.2 <sup>b</sup>	33.7 <sup>b</sup>	100.0 <sup>b</sup>	59.6
Wisconsin	53.2	51.9	54.4	53.3	52.1	54.6	49.1	41.3	49.2	40.6	59.6	-
Wyoming	53.5	49.1	58.3	53.2	48.7	58.0	-	-	-	-	-	-
Total	47.5	47.3	47.7	47.8	47.5	48.0	40.8	40.1	54.7	53.6	55.8	-

Abbreviations: 95% CI, 95% confidence interval; NS, net survival.

<sup>a</sup>Metropolitan registries.<sup>b</sup>Unstandardized estimates.